# A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies

> **NCT06820268** · PHASE1 · RECRUITING · sponsor: **NovaOnco Therapeutics Co., Ltd.** · enrollment: 168 (estimated)

## Conditions studied

- B-cell Lymphoma
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** XS-04 tablet

## Key facts

- **NCT ID:** NCT06820268
- **Lead sponsor:** NovaOnco Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-14
- **Primary completion:** 2027-11-01
- **Final completion:** 2028-03-15
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06820268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06820268, "A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06820268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*